Sunday, July 6, 2025 7/6/2025

A Population Based Study of Ketorolac and Ovarian Cancer Survival

Award Number: R01CA236789
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/14/2020
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

A Population Based Study of Ketorolac and Ovarian Cancer Survival - Ovarian cancer is the most deadly gynecologic cancer in the U.S. and most patients still die of chemo-resistant, recurrent disease. We propose that a FDA-approved analgesic may also have anti-tumor properties that will reduce recurrent disease and improve survival if given during or closely following ovarian cancer surgery. Racemic R,S-ketorolac (Toradol® or a generic equivalent) is an strong non-steroidal anti-inflammatory drug (NSAID) used in conjunction with surgeries. We have been investigating ketorolac since 2008 and have compelling preliminary evidence to support the hypothesis that ketroloac can help reduce ovarian cancer mortality. Our work is supported further by reported recurrence and mortality reduction with surgery-associated ketorolac administration in breast and lung cancer patients. Combined, this compelling evidence suggests that ketorolac will confer an anti-tumor benefit; however, a reduction in ovarian cancer mortality with surgery- associated ketorolac (vs. none) has not been demonstrated. We propose to address this gap in our knowledge with a population-based cohort study of ovarian cancer cases. We hypothesize that ovarian cancer cases that are given ketorolac as an analgesic during ovarian cancer surgery will have better overall survival than those who do not receive ketorolac, after accounting for factors such as co-morbidities, stage of disease and received treatment. In addressing this hypothesis, we will use an existing cohort of population-based ovarian cancer cases from Alberta and British Columbia, Canada, who were diagnosed from 2002 to 2012 with mortality followed through 2020, providing between 8 and 18 years of follow-up. We will complete de novo medical record reviews to ascertain co-morbidities and all analgesics and anesthesia used during surgery for ovarian cancer. Existing data/resources that are already in hand includes: details of cancer treatments received, standardized pathology review to classify the tumors by contemporary criteria, and tissue micro-arrays (TMAs) (all histotypes). Using these TMAs, we will use immunohistochemical staining of markers that may define subsets of patients to address our mechanistic hypothesis. If ketorolac given in the surgical period makes a substantial improvement in survival, then the use of ketorolac would be an efficient and widely applicable method to improve survival within normal medical practice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$22 )
2025	2023	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	000	5	5/19/2025	NON-COMPETING CONTINUATION	-$22
														Subtotal = -$22

Issue Date FY: 2023 ( Subtotal = $302,341 )
2023	2023	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	000	5	1/30/2023	NON-COMPETING CONTINUATION	$302,341
														Subtotal = $302,341

Issue Date FY: 2022 ( Subtotal = $338,423 )
2022	2022	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	003	4	4/26/2022	NON-COMPETING CONTINUATION	-$6,906
2022	2022	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	002	4	12/22/2021	NON-COMPETING CONTINUATION	$345,329
2022	2021	UNIVERSITY OF NEW MEXICO	1 UNIVERSITY OF NEW MEXICO	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Cause and Prevention Research	000	2	10/18/2021	NON-COMPETING CONTINUATION	-$109,885
2022	2021	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	001	3	10/18/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$109,885
														Subtotal = $338,423

Issue Date FY: 2021 ( Subtotal = $378,192 )
2021	2021	UNIVERSITY OF NEW MEXICO	2500 MARBLE DR NE	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Cause and Prevention Research	000	2	1/28/2021	NON-COMPETING CONTINUATION	$354,794
2021	2021	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Cause and Prevention Research	002	3	9/8/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$193,723
2021	2021	UNIVERSITY OF NEW MEXICO	2500 MARBLE DR NE	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Cause and Prevention Research	001	2	9/8/2021	NON-COMPETING CONTINUATION	-$170,325
														Subtotal = $378,192

Issue Date FY: 2020 ( Subtotal = $392,750 )
2020	2020	UNIVERSITY OF NEW MEXICO	2500 MARBLE DR NE	ALBUQUERQUE	NM	87131	BERNALILLO	USA	Cancer Cause and Prevention Research	000	1	2/14/2020	NEW	$392,750
														Subtotal = $392,750

Grand Total All Awards = $1,411,684

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Population Based Study of Ketorolac and Ovarian Cancer Survival

Award Number: R01CA236789

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/14/2020

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer